| 1 |
Du J, Lu C, Mao L, Zhu Y, Kong W, Shen S, Tang M, Bao S, Cheng H, Li G, Chen J, Li Q, He J, Li A, Qiu X, Gu Q, Chen D, Qi C, Song Y, Qian X, Wang L, Qiu Y, Liu B. PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial. Cell Rep Med 2023;4:100972. [PMID: 36889321 DOI: 10.1016/j.xcrm.2023.100972] [Reference Citation Analysis]
|
| 2 |
Okano N, Matsuki R, Toki M, Gondo K, Ochiai K, Watanabe S, Tateishi H, Kogure M, Suzuki Y, Sugiyama M, Nagashima F, Shibahara J, Sakamoto Y, Furuse J. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Intern Med 2023;62:327-34. [PMID: 35793961 DOI: 10.2169/internalmedicine.9504-22] [Reference Citation Analysis]
|
| 3 |
Ikenaga N, Miyasaka Y, Ohtsuka T, Nakata K, Adachi T, Eguchi S, Nishihara K, Inomata M, Kurahara H, Hisaka T, Baba H, Nagano H, Ueki T, Noshiro H, Tokunaga S, Ishigami K, Nakamura M; Kyushu Study Group of Treatment for Pancreatobiliary Cancer. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement. Ann Surg Oncol 2023;30:193-202. [PMID: 36207481 DOI: 10.1245/s10434-022-12566-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Ono Y, Inoue Y, Ito H, Sasaki T, Takeda T, Ozaka M, Sasahira N, Hiratsuka M, Matsueda K, Oba A, Sato T, Saiura A, Takahashi Y. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. HPB (Oxford) 2023;25:100-8. [PMID: 36280425 DOI: 10.1016/j.hpb.2022.09.012] [Reference Citation Analysis]
|
| 5 |
Gemcitabine/paclitaxel. Reactions Weekly 2022;1933:218-218. [DOI: 10.1007/s40278-022-28169-3] [Reference Citation Analysis]
|
| 6 |
Kobayashi K, Ono Y, Sato S, Kato T, Oba A, Sato T, Ito H, Inoue Y, Takamatsu M, Saiura A, Takahashi Y. Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy? Surgery 2022. [DOI: 10.1016/j.surg.2022.10.025] [Reference Citation Analysis]
|
| 7 |
Jung H, Kim HS, Kang JS, Kang YH, Sohn HJ, Byun Y, Han Y, Yun W, Cho YJ, Lee M, Kwon W, Jang J. Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers 2022;14:4360. [DOI: 10.3390/cancers14184360] [Reference Citation Analysis]
|
| 8 |
Takeda T, Sasaki T, Inoue Y, Okamoto T, Mori C, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Takahashi Y, Saiura A, Sasahira N. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Pancreatology 2022;22:507-15. [PMID: 35422382 DOI: 10.1016/j.pan.2022.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Hayashi K, Ono Y, Takamatsu M, Oba A, Ito H, Sato T, Inoue Y, Saiura A, Takahashi Y. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study. Ann Surg Oncol 2022. [PMID: 35230581 DOI: 10.1245/s10434-022-11471-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Oba A, Kato T, Del Chiaro M, Wu YHA, Inoue Y, Takahashi Y. Pancreaticoduodenectomy with Hepatic Artery Resection. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_40] [Reference Citation Analysis]
|
| 11 |
Wu YHA, Oba A, Lin R, Watanabe S, Meguid C, Schulick RD, Del Chiaro M. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. J Gastrointest Oncol 2021;12:2475-83. [PMID: 34790408 DOI: 10.21037/jgo-21-119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Hayasaki A, Kishiwada M, Murata Y, Komatsubara H, Nakagawa Y, Maeda K, Shinkai T, Noguchi D, Gyoten K, Fujii T, Iizawa Y, Tanemura A, Kuriyama N, Sakurai H, Isaji S, Mizuno S. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries. Pancreas 2021;50:1230-5. [PMID: 34714288 DOI: 10.1097/MPA.0000000000001902] [Reference Citation Analysis]
|
| 13 |
Furukawa T, Sasaki T, Ono Y, Kawano F, Takamatsu M, Mori C, Mie T, Yamada Y, Okamoto T, Takeda T, Kasuga A, Matsuyama M, Ozaka M, Takahashi Y, Sasahira N. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Clin J Gastroenterol 2021. [PMID: 34255287 DOI: 10.1007/s12328-021-01480-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Inoue Y, Ito H, Takahashi Y. Anatomical classification alone is not sufficient for optimal patient selection for neoadjuvant therapy versus upfront resection. J Hepatobiliary Pancreat Sci 2021;28:e15-6. [PMID: 33607703 DOI: 10.1002/jhbp.906] [Reference Citation Analysis]
|
